LIFVAYTA Trademark

Trademark Overview


On Friday, April 17, 2026, a trademark application was filed for LIFVAYTA with the United States Patent and Trademark Office. The USPTO has given the LIFVAYTA trademark a serial number of 99770366. The federal status of this trademark filing is PUBLISHED FOR OPPOSITION as of Tuesday, July 21, 2026. This trademark is owned by GENFIT. The LIFVAYTA trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical products for treating of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical purposes, namely, for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for pharmaceutical purposes, namely, for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical purposes; diagnostic testing materials for medical use in the nature of diagnostic testing agents and substances for medical use
lifvayta

General Information


Serial Number99770366
Word MarkLIFVAYTA
Filing DateFriday, April 17, 2026
Status686 - PUBLISHED FOR OPPOSITION
Status DateTuesday, July 21, 2026
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, July 21, 2026

Trademark Statements


Goods and ServicesPharmaceutical products for treating of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for medical purposes, namely, for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; chemical preparations for pharmaceutical purposes, namely, for the prevention and treatment of liver diseases, cholestatic diseases, metabolic diseases, cancer diseases, inflammatory diseases, autoimmune diseases and cancers; diagnostic preparations for medical purposes; diagnostic testing materials for medical use in the nature of diagnostic testing agents and substances for medical use

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, April 17, 2026
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameGENFIT
Party Type20 - Owner at Publication
Legal Entity Type33 - NOT AVAILABLE
AddressLoos 59120
FR

Party NameGENFIT
Party Type10 - Original Applicant
Legal Entity Type33 - NOT AVAILABLE
AddressLoos 59120
FR

Trademark Events


Event DateEvent Description
Friday, April 17, 2026APPLICATION FILING RECEIPT MAILED
Friday, April 17, 2026NEW APPLICATION ENTERED
Friday, April 17, 2026NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, May 19, 2026ASSIGNED TO EXAMINER
Tuesday, May 19, 2026NON-FINAL ACTION WRITTEN
Tuesday, May 19, 2026NON-FINAL ACTION E-MAILED
Tuesday, May 19, 2026NOTIFICATION OF NON-FINAL ACTION E-MAILED
Friday, June 19, 2026TEAS RESPONSE TO OFFICE ACTION RECEIVED
Friday, June 19, 2026CORRESPONDENCE RECEIVED IN LAW OFFICE
Friday, June 19, 2026TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, June 22, 2026DATA MODIFICATION COMPLETED
Tuesday, June 23, 2026APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, July 15, 2026NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, July 21, 2026PUBLISHED FOR OPPOSITION
Tuesday, July 21, 2026OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED